We have located links that may give you full text access.
After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Experimental and Clinical Endocrinology & Diabetes 2016 September
Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app